Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China

Q. Li, Y.T. Xiang, Y.A. Su, L. Shu, X. Yu, H.F.K. Chiu, C.U. Correll, Gabor Ungvari, K.Y.C. Lai, C. Ma, G.H. Wang, P.S. Bai, T. Li, L.Z. Sun, J.G. Shi, X.S. Chen, Q.Y. Mei, K.Q. Li, T.M. Si

    Research output: Contribution to journalArticle

    28 Citations (Scopus)

    Abstract

    © The Royal Australian and New Zealand College of Psychiatrists 2014. Objective: This study examined the use, demographic and clinical correlates of antipsychotic polypharmacy (APP) and its associations with treatment satisfaction and quality of life (QOL) in schizophrenia patients in China. Method: A total of 4239 patients in 45 nationwide Chinese psychiatric hospitals/centers were interviewed in 2012 in the third cross-sectional study, with the first two having been conducted in 2002 and 2006. Patients' socio-demographic and clinical characteristics, including psychopathology, side effects, satisfaction with treatment and QOL, were recorded using a standardized protocol and data collection procedure. Results: The proportion of APP prescriptions in 2012 was 34.2%, which was significantly higher than the frequency of APP in 2002 (26.1%) and 2006 (26.4%) (p2=0.31, p
    Original languageEnglish
    Pages (from-to)129-136
    JournalAustralian & New Zealand Journal of Psychiatry
    Volume49
    Issue number2
    DOIs
    Publication statusPublished - 2015

    Fingerprint Dive into the research topics of 'Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China'. Together they form a unique fingerprint.

    Cite this